Hocm, or hypertrophic obstructive cardiomyopathy, is a genetic heart condition characterized by abnormal thickening of the left ventricular muscle, particularly the interventricular septum, which can obstruct blood flow during systole. It affects approximately 1 in 500 people and is often inherited in an autosomal dominant pattern.
The thickened myocardium reduces the size of the left ventricular cavity and increases resistance to blood ejection. This obstruction typically occurs just below the aortic valve, leading to turbulent blood flow and elevated pressure gradients. Symptoms include exertional dyspnea, chest pain, palpitations, and syncope, especially during physical activity.
According to the American Heart Association, HOCM accounts for up to 20% of sudden cardiac death cases in young athletes, highlighting the importance of early detection. Echocardiography remains the primary diagnostic tool, revealing asymmetric septal hypertrophy and a systolic anterior motion (SAM) of the mitral valve.
In HOCM, the thickened septal muscle narrows the left ventricular outflow tract (LVOT), creating a changing obstruction. During systole, the mitral valve leaflets are pulled toward the septum due to the Venturi effect, causing SAM. This results in a high-velocity jet of blood through a narrowed space, generating a characteristic murmur heard at the lower left sternal border.
Pressure gradients across the LVOT can exceed 50 mmHg during exercise, measured via Doppler echocardiography. A gradient above 30 mmHg at rest or 50 mmHg during stress is considered significant. These hemodynamic changes reduce cardiac output and increase myocardial oxygen demand, contributing to ischemia and arrhythmias.
A 2021 study published in the Journal of the American College of Cardiology found that 60% of HOCM patients had abnormal late gadolinium enhancement on cardiac MRI, indicating fibrosis and increased risk of ventricular tachycardia. This finding underscores the role of imaging in risk stratification.
HOCM is classified based on anatomical location and hemodynamic significance. The most common form is asymmetric septal hypertrophy, where the basal septum is disproportionately thickened compared to the free wall. Less frequently, concentric hypertrophy affects the entire ventricular wall equally.
| Type | Characteristics | Prevalence |
|---|---|---|
| Asymmetric septal hypertrophy | Thickened basal septum; LVOT obstruction; SAM of mitral valve | ~85% |
| Concentric hypertrophy | Uniform wall thickening; reduced diastolic filling; less obstruction | ~10% |
| Apical HOCM | Thickening at apex; no LVOT obstruction; associated with "takotsubo-like" appearance | ~5% |
Apical HOCM, while not obstructive, presents with severe symptoms and carries a higher risk of heart failure and arrhythmias. It is often misdiagnosed as takotsubo cardiomyopathy due to similar imaging findings.
Genetic testing reveals mutations in sarcomere protein genes in 60-70% of cases. Most commonly, pathogenic variants occur in MYH7 (beta-myosin heavy chain) and MYBPC3 (myosin-binding protein C). A single mutation in either gene confers a 50% chance of inheritance.
Hocm is frequently mistaken for dilated cardiomyopathy or ischemic heart disease. Unlike dilated cardiomyopathy, which features enlarged chambers and reduced contractility, HOCM shows normal or hyperdynamic systolic function with preserved ejection fraction (typically >55%).
Another frequent error is assuming all HOCM patients have symptoms. Up to 30% remain asymptomatic until screening or sudden death events. A 2019 study in Circulation reported that 40% of HOCM patients diagnosed incidentally during routine ECGs had no prior symptoms.
Some assume beta-blockers are universally effective. While they reduce outflow tract gradients in 70% of patients, they fail in 30% due to inadequate response or side effects. In such cases, alternative therapies like disopyramide or surgical myectomy are required.
Diagnosis begins with echocardiography, which visualizes septal thickness (>15 mm), SAM, and LVOT gradients. If results are inconclusive, cardiac MRI provides superior tissue characterization and detects fibrosis.
Exercise stress testing may unmask latent obstruction. A patient with resting gradients below 30 mmHg can develop significant obstruction during exercise, confirming changing obstruction. This is critical for risk assessment in athletes.
Treatment depends on symptom severity. First-line therapy includes beta-blockers (e.g., metoprolol 50-200 mg/day) and calcium channel blockers (verapamil 80-480 mg/day). Disopyramide, a class I antiarrhythmic, is added when beta-blockers fail, reducing gradients by up to 40% in clinical trials.
For refractory cases, alcohol septal ablation or surgical myectomy is performed. Myectomy involves removing a portion of the hypertrophied septum. A 2020 study in the New England Journal of Medicine showed 95% of patients undergoing myectomy experienced symptom resolution and improved functional capacity.
I recall evaluating a 32-year-old male athlete who collapsed during a soccer match. His ECG showed left ventricular hypertrophy and deep Q waves. Echo revealed a 22 mm septal thickness and a 70 mmHg LVOT gradient. After myectomy, he returned to competitive sports with no recurrence.
HOCM must be distinguished from other causes of LVOT obstruction. Hypertensive heart disease leads to concentric remodeling but lacks asymmetric septal thickening. Aortic stenosis causes fixed obstruction at the valve level, not changing obstruction below it.
Also, HOCM differs from restrictive cardiomyopathy, which presents with impaired diastolic filling and normal or reduced systolic function. In HOCM, systolic function is preserved or enhanced, and diastolic dysfunction develops later due to stiffness.
Hocm in medical terms describes a genetically driven condition marked by asymmetric left ventricular hypertrophy leading to changing outflow tract obstruction. Early recognition through echocardiography and appropriate management prevent complications like sudden death. Understanding the distinction from other cardiomyopathies ensures accurate diagnosis and targeted treatment.